CRIDD: Comparison of Remowell 2 and Inspire on Delirium and Cognitive Dysfunction

Sponsor
Maria Cecilia Hospital (Other)
Overall Status
Unknown status
CT.gov ID
NCT04062396
Collaborator
(none)
314
1
2
29.1
10.8

Study Details

Study Description

Brief Summary

Age is no longer an absolute contraindication to cardiac surgery therefore there is often need for combined interventions (double valve repair/replacement, or coronary artery bypass graft and valve repair/replacement) with relative prolongation of cardiopulmonary bypass time. Prolonged cardiopulmonary bypass use causes an increase in the inflammatory response, and on the other a need for blood reinfusion and therefore lipid microemboli from the operative field. The clinical consequences for patients are post-operative delirium and post-operative cognitive impairment.

These two neurological complications involve up to 45% of elderly patients undergoing cardiac surgery and have a significant impact on quality of life, hospitalization and mortality in the short and long term. The Remowell 2 oxygenator system has demonstrated in preliminary studies that, compared to the gold standard Inspire oxygenator, it can guarantee a significant reduction of hemodilution, inflammatory systemic response and embolization of lipid microemboli and leukocytes. In light of these considerations, it is possible to formulate the hypothesis that the use of the Remowell 2 device can contribute to significantly reducing the onset of post-operative delirium and cognitive impairment. The present study is designed to validate this hypothesis in a randomized controlled scenario.

Condition or Disease Intervention/Treatment Phase
  • Device: Eurosets REMOWELL 2 oxygenator
  • Device: LivaNova INSPIRE oxygenator
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
314 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Randomized Comparison Between Oxygenator Systems for the Reduction of Post-operative Delirium in Older Patients Undergoing Cardiac Surgery
Actual Study Start Date :
Sep 26, 2019
Anticipated Primary Completion Date :
Mar 1, 2021
Anticipated Study Completion Date :
Mar 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Eurosets REMOWELL 2 oxygenator

Device: Eurosets REMOWELL 2 oxygenator
The main characteristic of REMOWELL 2 oxygenator is the presence of a filtration system for extracavitary inlet. Multilayer cascade filtration and supernatant separator leads to lipid-leukocytes depletion

Active Comparator: LivaNova INSPIRE oxygenator

Device: LivaNova INSPIRE oxygenator
INSPIRE oxygenator has no filtration system for extracavitary inlet

Outcome Measures

Primary Outcome Measures

  1. post-operative delirium [6 days]

    In-hospital incidence of post-operative delirium assessed by Confusion Assessment Method (CAM) diagnostic algorithm

Eligibility Criteria

Criteria

Ages Eligible for Study:
65 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Signature of informed consent for participation in the study

  2. Age ≥65 years

  3. Patients undergoing cardiac surgery of:

  4. coronary artery bypass graft and concomitant valve replacement/repair OR

  5. double valve replacement/repair

Exclusion Criteria:
  1. Any documented history of cognitive impairment estimated as a mini mental state examination < 24 points

  2. Patients who need blood prime in the cardiopulmonary bypass circuit

  3. Chronic coagulopathies ( international normalized ratio > 2 in patients without anticoagulant treatment)

  4. End stage renal disease on dialysis treatment

  5. Previous cerebrovascular accident

  6. Active cancer or immunological diseases

  7. Liver cirrhosis (platelets <100.000/uL)

  8. Decompensated diabetes

  9. Severe preoperative anemia (hemoglobin <8 g/dl).

Contacts and Locations

Locations

Site City State Country Postal Code
1 Maria Cecilia Hospital Cotignola Ravenna Italy 48010

Sponsors and Collaborators

  • Maria Cecilia Hospital

Investigators

  • Principal Investigator: Lorenzo Mantovani, MD, Maria Cecilia Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Maria Cecilia Hospital
ClinicalTrials.gov Identifier:
NCT04062396
Other Study ID Numbers:
  • MCH2019-01
First Posted:
Aug 20, 2019
Last Update Posted:
Sep 30, 2019
Last Verified:
Aug 1, 2019
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 30, 2019